NextCure, Inc. (NASDAQ:NXTC)
| Market Cap | 23.70M+7.0% |
| Revenue (ttm) | 0 |
| Net Income | -42.75M+29.8% |
| EPS | -10.58+59.2% |
| Shares Out | 3.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,376 |
| Open | 5.70 |
| Previous Close | 5.68 |
| Day's Range | 5.42 - 6.70 |
| 52-Week Range | 1.55 - 15.74 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 20.00(+204.88%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NXTC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NXTC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NXTC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NXTC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NXTC Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Upfront cash payment | $12.00M | 57.49% |
| Clinical product candidates | $4.25M | 20.36% |
| Employee costs | $1.54M | 7.36% |
| Professional services | $1.16M | 5.56% |
| Nonclincal product candidates | $746.00K | 3.57% |
| Other R&D | $628.00K | 3.01% |
| Other G&A | $322.00K | 1.54% |
| Insurance | $233.00K | 1.12% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NXTC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NXTC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NXTC
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $787.73K |
| VXFVanguard Extended Market ETF | $214.49K |
| IWCiShares Micro-Cap ETF | $53.05K |
| PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | $20.66K |
| DFMCU.S. Micro Cap Portfolio ETF | $15.41K |
| DFACDimensional - US Core Equity 2 ETF | $335.42 |
Estimated from each fund’s disclosed top holdings × AUM
NXTC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NXTC’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score